On course to publish our scientific research and findings.

We are committed to publishing the results from our pre-clinical and clinical research in collaboration with the scientists, physicians, researchers and others with whom we collaborate at medical meetings and in peer-reviewed publications.

Filter:
Date Type Description Link
Dec 2023 Journal Papers

Hurrish, et. al., Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro. Biochem Pharmacol. 2023 Dec 9:115981.

https://www.sciencedirect.com/science/article/abs/pii/S0006295223005749?via%3Dihub
Dec 2023 Poster

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

/images/ASH_2023_Voruciclib_Poster_Final.pdf
Dec 2021 Poster

A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML, 63rd ASH Annual Meeting, December 2021

/sites/meipharma-corp/files/mei-pharma/pipeline/publications/ash-2021-vorucicli…
Apr 2021 Poster

Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models, AACR Annual Meeting 2021

/sites/meipharma-corp/files/mei-pharma/pipeline/publications/voruciclib-poster…
Feb 2020 Journal Papers

Luedtke, et al. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020 Feb 26;5(1):17.

https://pubmed.ncbi.nlm.nih.gov/32296028/
Dec 2018 Poster

Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced by the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia

/sites/meipharma-corp/files/mei-pharma/media/ash2018-voruciclib-luedtke.pdf
Dec 2017 Journal Papers

Dey, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007.

https://www.nature.com/articles/s41598-017-18368-w
Jul 2016 Journal Papers

Eliades, et al. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 2;17(7):778-84.

https://pubmed.ncbi.nlm.nih.gov/26810603/
Apr 2016 Poster

Voruciclib, a clinical stage CDK inhibitor sensitizes triple negative breast cancer xenografts to proteasome inhibition. AACR Annual Meeting, April 2016

/sites/meipharma-corp/files/mei-pharma/media/voruciclib-aacr-2016.pdf
Nov 2015 Journal Papers

Paiva, et al. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One. 2015 Nov 25;10(11)

https://pubmed.ncbi.nlm.nih.gov/26606677/
Jun 2015 Poster

Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. ASCO Annual Meeting, June 2015

/sites/meipharma-corp/files/mei-pharma/media/voruciclib-braf-combo-asco-2015.pdf